Clinical Evaluation of the Use of Exemestane as Further Hormonal Therapy after Nonsteroidal Aromatase Inhibitors in Postmenopausal Metastatic Breast Cancer Patients
- 1 January 2007
- journal article
- research article
- Published by Taylor & Francis in Cancer Investigation
- Vol. 25 (2) , 102-105
Abstract
Objectives.The aromatase inhibitors Anastrozole, Letrozole (type 2 nonsteroidal aromatase inhibitors: n-SAI) and Exemestane (type 1 steroidal aromatase inactivator) are used respectively as first- and second-line hormonal therapy in postmenopausal metastatic breast cancer women. Few clinical data are published on the sequential use of different classes of aromatase inhibitors. Methods. We report an analysis on 30 postmenopausal metastatic breast cancer women treated between January 2000 and May 2002 in 2 Italian Oncology Institutions with the hormonal sequence n-SAI (Anastrozole, Letrozole) → Exemestane. Results. When receiving n-SAI (Anastrozole 8 patients and Letrozole 22 patients), 1 out of 30 women achieved a partial response, 20 of 30 patients no change (NC) ≥6 months. The analysis of the entire population treated with Exemestane showed an overall clinical benefit (CB) of 46.6 percent (14/30) with a median duration of 12 months (95%CI 6–25) and a median time to progression (TTP) of 4 months (95%CI 1–25). Conclusions. These data confirm a partial lack of cross-resistance between n-SAI → Exemestane given in sequence.Keywords
This publication has 19 references indexed in Scilit:
- Phase III, Multicenter, Double-Blind, Randomized Study of Letrozole, an Aromatase Inhibitor, for Advanced Breast Cancer Versus Megestrol AcetateJournal of Clinical Oncology, 2001
- Antiaromatase Agents: Preclinical Data and Neoadjuvant TherapyClinical Breast Cancer, 2000
- ExemestaneDrugs, 2000
- Exemestane Is Superior to Megestrol Acetate After Tamoxifen Failure in Postmenopausal Women With Advanced Breast Cancer: Results of a Phase III Randomized Double-Blind TrialJournal of Clinical Oncology, 2000
- Treatment of Breast CancerNew England Journal of Medicine, 1998
- Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinomaCancer, 1998
- Aromatase inhibitors in advanced breast cancer: mechanism of action and clinical implicationsThe Journal of Steroid Biochemistry and Molecular Biology, 1998
- Letrozole, a new oral aromatase inhibitor: Randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancerAnnals of Oncology, 1998
- Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate.Journal of Clinical Oncology, 1998
- Aromatase inhibitorsEndocrine-Related Cancer, 1996